comparemela.com

Europe Suzhou Sheng News Today : Breaking News, Live Updates & Top Stories | Vimarsana

复宏汉霖(02696 HK):斯鲁利单抗注射液联合化疗一线治疗局部晚期或转移性鳞状非小细胞肺癌的上市注册申请(NDA)获国药监局受理 _ 东方财富网

复宏汉霖(02696.HK)宣布,近日,公司自主开发的斯鲁利单抗注射液(重组抗PD-1人源化单克隆抗体注射液)(“斯鲁利单抗注射液”)联合卡铂和白蛋白紫杉醇一线治疗局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)的上市注册申请(NDA)获国家药品监督管理局(“NMPA”)药品审评中心受理。该适应症为斯鲁利单抗注射液于中国大陆境内第二项申报上市的适应症。

复宏汉霖(02696 HK):斯鲁利单抗注射液获NMPA药品审评中心纳入优先审评审批程序_个股资讯_市场_中金在线

复宏汉霖(02696 HK):斯鲁利单抗注射液获NMPA药品审评中心纳入优先审评审批程序_个股资讯_市场_中金在线
cnfol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnfol.com Daily Mail and Mail on Sunday newspapers.

复宏汉霖-B(02696 HK):斯鲁利单抗注射液上市注册申请获国家药监局受理并拟纳入优先审评_个股资讯_市场_中金在线

复宏汉霖-B(02696 HK):斯鲁利单抗注射液上市注册申请获国家药监局受理并拟纳入优先审评_个股资讯_市场_中金在线
cnfol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnfol.com Daily Mail and Mail on Sunday newspapers.

复宏汉霖-B(02696 HK):斯鲁利单抗注射液上市注册申请获国家药监局受理并拟纳入优先审评 _ 东方财富网

复宏汉霖-B(02696 HK):斯鲁利单抗注射液上市注册申请获国家药监局受理并拟纳入优先审评 _ 东方财富网
eastmoney.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastmoney.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.